
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announced that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB™, at the Royal Adelaide Hospital ('RAH'). The clinical study which is being conducted by the Central Adelaide Local Health Network ('CALHN') is co-funded by Telix and strategic partner, AusHealth®.

The study, which is being led by RAH Cancer Clinical Trials Unit Head Professor Michael Brown, is a two-arm trial of an antibody that targets the La/SSB protein (APOMAB™) initially labelled with Zirconium-89 (⁸⁹Zr-APOMAB) to enable the biological and targeting properties of the agent to be evaluated using positron emission tomography (PET). The target of APOMAB, the La/SSB protein, is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation, and the research objective of the study is to evaluate how well APOMAB is able to potentially deliver diagnostic and therapeutic targeted radiation to advanced lung or ovarian cancers.¹ The trial will enrol 18 patients in total.

The trial's principle investigator Professor Michael Brown said "The dosing of these first patients is the culmination of more than a decade of fundamental research around a novel oncology target, and enables the evaluation of the potential of APOMAB as a targeting agent for imaging and therapy."

Telix CEO Dr Chris Behrenbruch said "This clinical proof-of-concept study will test the suitability of the APOMAB technology to deliver targeted radiation to lung and ovarian cancers, two areas of cancer care where there is a significant unmet medical need to provide patients with additional therapeutic options. We believe that APOMAB has the potential to be used for multiple cancer indications and we're particularly pleased to be supporting an Australian researcher of the calibre of Professor Brown, who is highly recognised as a pioneer in this field."

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

About AusHealth®

AusHealth® is a national Profit-for-Purpose company that supports the commercialisation of innovative medical technologies, improving the health of all through three divisions: AusHealth® Research, AusHealth® Work and AusHealth® Hospitals. All profits fund medical research and development of products and services that look to improve future of medical practice. Since 1985, AusHealth® has helped people with diabetes, joint damage, cardiovascular disease, and cancer; as well as improving burn & scar and foetal health diagnostics. Other commercial success stories by AusHealth® include Mesoblast (ASX:MSB), LBT Innovations (ASX:LBT) and Firefly Health. Visit www.aushealth.com.au.

¹ Australian New Zealand Clinical Trials Registry registration number: ACTRN12620000622909

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.